Vaccine Co-Development and Technology Transfer
we are conducting various joint development and technology transfer projects with global companies
from material supply to product development, clinical trials, and sales.
Joint development
We provide the best solution for faster product development with advanced systems for core competitive R&D
and manufacturing processes and future-oriented investments in joint development.
- 2.5 Years
- R&D
- NCS (tox)
- 1 Year
- PhaseⅠ/Ⅱ
- 3 Years
- Construction
- CTM* manufacturing
- 2 Years
- Phase Ⅲ
- 1 Year
- BLA
- 2.5 Years
- R&D
- NCS(tox)
- 1 Year
- PhaseⅠ/Ⅱ
-
- Construction
- CTM* manufacturing
- 1.5 Years
- Phase Ⅲ
- 0.8 Year
- BLA
from scratch
to the market
Joint development process
- Full or partial funding
-
Preclinical process development
Small scale
manufacturingBIO R&D CENTER
-
Clinical
Commercial scale
manufacturingL HOUSE
- BLA/WHO PQ
-
Supply
Post marketing
commitment
We are working with various global companies and foundations for global healthcare.
PCV
R&D, production and marketing
for next generation PCV in 2014
TCV
Co-development with IVI
(Bill & Melinda Gates Foundation) in 2013
NRRV
Modern co-development with PATH
(Bill & Melinda Gates Foundation) in 2017
COVID 19
(NBP2001)
Development of a recombinant protein vaccine with funding from the Korea Disease Control and Prevention Agency, Ministry of Health and Welfare, and Ministry of Trade, Industry & Energy
COVID 19
(GBP510)
Study of a recombinant protein vaccine candidate (GBP510)—manufactured using a nanoparticle platform—and manufacture of clinical trial materials needed for phase I/II and phase III trials
Sarbecovirus
Development of a general-purpose vaccine for Sarbecovirus under CEPI supported
Nasal Spray
Co-developement with Bill&Melinda Gates Foundation, IAVI, IPD
